Immunovant, Inc. — Fiscal 2024 Form 10-K Summary
Business context and reporting period
Immunovant is a clinical-stage immunology company developing anti-FcRn antibodies for IgG-mediated autoimmune diseases. Its lead candidate is IMVT-1402, with batoclimab as an additional development program. Neither candidate is approved for commercial sale, and the company has generated no product revenue.
The filing covers the fiscal year ended March 31, 2024, with comparative results for the year ended March 31, 2023. The company reports one operating segment and is listed on Nasdaq under IMVT. Roivant Sciences Ltd. beneficially owned approximately 54.6% of voting power as of May 22, 2024.
Financial performance and liquidity
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $212.9 million | $160.3 million | +$52.7 million |
| Acquired in-process R&D | $12.5 million | $10.0 million | +$2.5 million |
| General and administrative expense | $57.3 million | $48.0 million | +$9.3 million |
| Total operating expenses | $282.7 million | $218.3 million | +$64.4 million |
| Interest income | $24.9 million | $7.6 million | +$17.4 million |
| Net loss | $259.3 million | $211.0 million | Loss increased by $48.4 million |
| Net loss per share | $1.88 | $1.71 | Loss per share increased |
| Cash used in operating activities | $214.2 million | $188.2 million | Use increased by $26.0 million |
| Cash and cash equivalents | $635.4 million | $376.5 million | +$258.8 million |
R&D spending increased primarily because IMVT-1402 development costs rose to $43.1 million from $10.3 million, while personnel-related R&D costs increased to $75.0 million from $49.8 million. Batoclimab program-specific costs declined to $74.3 million from $78.5 million.
Cash and cash equivalents included approximately $607.7 million in money market funds. The company reported no debt balance in the consolidated balance sheets. Total liabilities were $48.6 million, including $41.3 million of accrued expenses. Accumulated deficit was $825.7 million at March 31, 2024. Profit margins are not meaningful because the company has no revenue and remains loss-making.
Financing activities provided $472.4 million of cash, principally from an October 2023 public offering and concurrent private placement. The company received net proceeds of approximately $466.7 million and issued 12.95 million shares in those transactions. An additional $150.0 million ATM program was established, but no shares had been sold under it as of March 31, 2024.
Material changes versus the prior comparable period
- Net loss increased 23% to $259.3 million, driven by higher clinical development, personnel, and corporate costs.
- R&D expense increased 33%, reflecting expanded IMVT-1402 development and higher headcount and capabilities.
- Operating cash burn increased to $214.2 million from $188.2 million.
- Liquidity increased substantially following the $466.7 million October 2023 equity financing.
- Interest income increased materially because of higher cash balances and prevailing rates.
- The company achieved two HanAll development and regulatory milestones totaling $12.5 million, recorded as acquired in-process R&D expense.
- Stock-based compensation increased to $41.0 million from $32.0 million.
Clinical progress, outlook, and unusual items
- In a Phase 1 healthy-volunteer study, IMVT-1402 reduced mean total IgG by 63% after four weekly 300 mg doses and 74% after four weekly 600 mg doses. The company reported no or minimal albumin reductions or LDL increases in the evaluated cohorts, with generally mild or moderate adverse events.
- Batoclimab Graves’ disease data showed mean IgG reduction of 81% after 12 weeks at 680 mg, with reductions of up to 87%; the Phase 2 study remains ongoing.
- The company expects to initiate four to five potentially registrational IMVT-1402 programs by March 31, 2025, and trials in ten indications by March 31, 2026.
- Management expects additional Graves’ disease program information in fall 2024, batoclimab myasthenia gravis top-line data by March 31, 2025, and thyroid eye disease top-line data in the first half of calendar 2025.
- The company may transition CIDP, MG, and TED registrational programs from batoclimab to IMVT-1402 depending on clinical data.
- Management expects March 31, 2024 cash and cash equivalents to fund operating and capital expenditure requirements for at least the next 12 months from the filing date, but states that current funds will not be sufficient to complete all development and potential commercialization activities.
- Remaining minimum purchase obligations to Samsung for batoclimab manufacturing were approximately $46.2 million, with payments scheduled through fiscal 2029.
- Under the HanAll Agreement, up to $420.0 million of additional regulatory and sales milestones may become payable, plus tiered royalties ranging from the mid-single digits to mid-teens percentage of net sales if products are commercialized.
- A securities class-action lawsuit was dismissed with prejudice, judgment was entered for defendants in April 2024, and plaintiffs did not appeal. The litigation is concluded.
Key risks and contingencies
- The company has no approved products, no product revenue, and expects significant operating losses and negative cash flows for the foreseeable future.
- Clinical trials may fail, be delayed, suffer enrollment or retention problems, or produce safety or efficacy results that do not support regulatory approval.
- Batoclimab previously produced dose-related LDL and cholesterol increases associated with albumin reductions, creating ongoing long-term safety and regulatory risks.
- IMVT-1402 data are based primarily on early-stage healthy-volunteer results and may not predict results in patients or pivotal trials.
- The company depends on CROs, contract manufacturers, suppliers, and other third parties, including Samsung, for clinical execution and manufacturing.
- Additional capital will be required; future equity financing could dilute shareholders, while debt or collaboration financing could impose restrictive terms or require surrendering rights.
- The company relies on the HanAll license for core intellectual property, and termination or breach could materially impair development and commercialization rights.
- Competition is substantial, including approved or developing FcRn inhibitors such as efgartigimod and rozanolixizumab, as well as therapies with other mechanisms.
- Roivant’s majority voting control may limit minority stockholders’ influence over directors, equity issuances, amendments, and strategic transactions.
- Manufacturing, geopolitical, macroeconomic, reimbursement, intellectual-property, privacy, cybersecurity, and regulatory risks could materially affect development timelines and future financial results.
Facts investors should verify
- Whether IMVT-1402’s early IgG-reduction and lipid-profile results are replicated in patient populations and registrational trials.
- Timing, enrollment, endpoints, safety findings, and final results for batoclimab MG, CIDP, GD, and TED programs.
- Whether the planned IMVT-1402 programs are initiated on schedule and whether any programs transition from batoclimab.
- Cash burn, remaining liquidity, expected runway, and the timing and terms of any additional financing.
- Potential HanAll milestone payments, royalties, and the $46.2 million Samsung manufacturing commitment.
- Regulatory feedback, BLA planning, manufacturing readiness, and any safety-related requirements or clinical holds.
- Competitive developments and approvals affecting MG, CIDP, GD, TED, and other anti-FcRn indications.
- The effect of Roivant’s control, equity compensation dilution, and the company’s $150.0 million unused ATM capacity.
The financial statements received an unqualified audit opinion from Ernst & Young LLP, and management and the auditor concluded that internal control over financial reporting was effective as of March 31, 2024.